Dosimetry and preclinical evaluation of long-term radiotoxicity following treatment with 212Pb alpha-radioimmunotherapy targeting CD20
This study shows that long-term toxicity is induced by [<sup>212</sup>Pb]Pb-TCMC-rituximab, particularly affecting the kidneys. However, it highlights that this renal toxicity can be reduced through optimization, possibly by modifying the specific activity of the treatment.
Authors
- Erick Mora‐Ramirez (ORCID: https://orcid.org/0000-0003-1794-6559)
- Stéphanie Durand-Panteix (ORCID: https://orcid.org/0000-0003-4730-0070)
- Amal Saidi
- Isabelle Quelven (ORCID: https://orcid.org/0000-0002-5877-8937)
- Magali Sage
- Michel Cogné (ORCID: https://orcid.org/0000-0002-8519-4427)
- Julien Torgue (ORCID: https://orcid.org/0000-0002-5898-1521)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Universidad de Costa Rica (CR)
- Toulouse Mathematics Institute (FR)
- Hôpital Purpan (FR)
- Orano (France) (FR)
- Université de Rennes (FR)
- Université de Limoges (FR)
Publication Details
- Journal
- EJNMMI Research
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1186/s13550-025-01349-w
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00